Actively Recruiting
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Led by Emory University · Updated on 2025-04-20
140
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
CONDITIONS
Official Title
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men or women aged 18 to 65 years
- Willing and able to give written informed consent
- For MDD patients: primary diagnosis of current Major Depressive Disorder by DSM-V and SCID-I
- Beck Depression Inventory score of 20 or higher indicating moderate to very severe symptoms
- Off all antidepressant therapy for at least 8 weeks before baseline visit
- For healthy controls: no psychiatric disorder except mild past substance use disorder
You will not qualify if you...
- History of bipolar or psychotic disorder
- Active psychotic symptoms
- Substance abuse or dependence within 6 months before study
- Unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease
- Active suicidal ideation with score 3 or higher on Columbia Suicide Severity Rating Scale
- Use of recreational drugs confirmed by urine drug screen at scanning
- Pregnancy or lactation
- Use of glucocorticoids during study
- Raynaud's disease interfering with cold-pressor test
- Contraindications for MRI
- Mini-Mental State Examination score below 28
- Elevated blood pressure prior to infusion (systolic >160 or diastolic >100)
- History of treatment resistance or prior adverse reaction to ketamine
- Use of antipsychotic medications or high-dose benzodiazepines (>2mg lorazepam daily)
- Regular smoking as self-reported
- For healthy controls: evidence of psychiatric disorder except specific phobia
- Substance abuse history within last 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
M
Michael Treadway, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here